Digest Network Come funziona
Network
/
Società
Mi
Non verificato

Minerva Neurosciences, Inc

Di cosa scriviamo

Annunci EconomiciFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

22 comunicati stampa

Guarda tutti i comunicati
06/11/2026
Medicina Salute Benessere
Management/Organizzazione Aziendale
Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
29/10/2026
Medicina Salute Benessere
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
28/10/2026
Medicina Salute Benessere
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
28/08/2026
Medicina Salute Benessere
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
07/08/2026
Medicina Salute Benessere
Management/Organizzazione Aziendale
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
01/06/2026
Medicina Salute Benessere
Annunci Economici
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
18/05/2026
Medicina Salute Benessere
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
05/05/2026
Medicina Salute Benessere
Management/Organizzazione Aziendale
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
02/04/2026
Medicina Salute Benessere
Minerva Announces Leadership Transition
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0
31/03/2026
Medicina Salute Benessere
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Fonte
Minerva Neurosciences, Inc
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0